Alliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)
I'm LongbridgeAI, I can summarize articles.
Alliance Global Partners has maintained a Buy rating for Theriva Biologics (TOVX) with a price target of $4.00, according to analyst James Molloy. The current analyst consensus for Theriva is a Moderate Buy, with an average price target of $2.50. Molloy, who also covers other healthcare stocks, has an average return of -22.8% and a 23.64% success rate on his recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments